AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15650802 — intervention group
Group type: COMPARATOR
Intervention: Unilateral total and contralateral subtotal thyroidectomy (Group B)
Number of subjects: 340
Study 12922963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 53
Study 12922963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10634923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling with fortified drink supplements (group B)
Number of subjects: 50
Study 10634923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling with normal food (group A)
Number of subjects: 50
Study 10634923 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 50
Study 7972617 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (5 mg i.v.)
Number of subjects: 20
Study 7972617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7972617 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact heat
Number of subjects: 20
Study 7972617 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin sensitivity for nonnoxious stimuli (warmth, cold, vibration)
Number of subjects: 20
Study 2784061 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31
Study 2784061 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 31
Study 45539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.8 mg sublingual
Number of subjects: 20
Study 45539 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 20
Study 45539 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 25 mg
Number of subjects: 20
Study 45539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (LFX) 2.4 mg/day
Number of subjects: 57
Study 31448846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 57
Study 28453452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training using the HUBER exercise system for 5 weeks (10 sessions)
Number of subjects: 53
Study 28453452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training using the HUBER exercise system
Number of subjects: 53
Study 25770433 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 2693
Study 25770433 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cigarette use
Number of subjects: 2693
Study 25770433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual use
Number of subjects: 2693
Study 23949882 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/week, with dose escalation until serum total testosterone of 20 nmol/l)
Number of subjects: 42
Study 20605150 — intervention group
Group type: EXPERIMENTAL
Intervention: External Aortic Compression Device (EACD)
Number of subjects: 120
Study 20605150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EACD)
Number of subjects: 120
Study 18068369 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic limbic leukotomy (subcaudate tractotomy and cingulotomy) via radiofrequency thermocoagulation
Number of subjects: 16
Study 16368630 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement imagery
Number of subjects: 30
Study 16368630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching imagery
Number of subjects: 30
Study 16368630 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 12800099 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/d) for 12 weeks
Number of subjects: 118
Study 12800099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rosiglitazone)
Number of subjects: 118
Study 10819830 — intervention group
Group type: EXPERIMENTAL
Intervention: semi‐Fowler position
Number of subjects: 108
Study 10819830 — intervention group
Group type: COMPARATOR
Intervention: left lateral recumbent position
Number of subjects: 108
Study 8781766 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200, 400, 600, or 800 mg once daily, or 200 or 400 mg twice daily)
Number of subjects: 330
Study 8781766 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 330
Study 8781766 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (600 and 800 mg/day)
Number of subjects: 330
Study 8781766 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 and 600 mg doses)
Number of subjects: 330
Study 8781766 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (highest doses)
Number of subjects: 330
Study 8781766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 1311974 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (n = 11)
Number of subjects: 22
Study 1311974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 22
Study 3884746 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-diamminedichloroplatinum (DDP)
Number of subjects: 135
Study 3884746 — intervention group
Group type: COMPARATOR
Intervention: combination of cyclophosphamide (CTX), Adriamycin (ADR), and DDP (CAD)
Number of subjects: 135
Study 29297769 — intervention group
Group type: EXPERIMENTAL
Intervention: Video visits with remote specialists
Number of subjects: 183
Study 29297769 — intervention group
Group type: EXPERIMENTAL
Intervention: Video visits
Number of subjects: 183
Study 29231524 — intervention group
Group type: EXPERIMENTAL
Intervention: Need-in-row combined with herb-partition moxibustion
Number of subjects: 105
Study 29231524 — intervention group
Group type: EXPERIMENTAL
Intervention: Need-in-row therapy
Number of subjects: 105
Study 29231524 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 105
Study 24863090 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training program (60 minutes of aerobic and stretching exercises, twice a week for 12 weeks)
Number of subjects: 33
Study 24863090 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training program
Number of subjects: 33
Study 24863090 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained patients)
Number of subjects: 33
Study 22038992 — intervention group
Group type: COMPARATOR
Intervention: 0% crude glycerol
Number of subjects: 172
Study 22038992 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% crude glycerol
Number of subjects: 172
Study 22038992 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% crude glycerol
Number of subjects: 172
Study 22038992 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% crude glycerol
Number of subjects: 172
Study 22038992 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% crude glycerol
Number of subjects: 172
Study 22038992 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% crude glycerol
Number of subjects: 172
Study 20337621 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 20337621 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 18407904 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein powder supplement aiming at 36 g of protein per day
Number of subjects: 90
Study 18407904 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and protein supplements aiming at 37.6 g of protein and 500 kcal per day
Number of subjects: 90
Study 18407904 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 90
Study 15759528 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching package for nurses to improve patient positioning
Number of subjects: 120
Study 15759528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no teaching package)
Number of subjects: 120
Study 12450709 — intervention group
Group type: EXPERIMENTAL
Intervention: Air drying
Number of subjects: 130
Study 12450709 — intervention group
Group type: EXPERIMENTAL
Intervention: Maleic acid
Number of subjects: 130
Study 12450709 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond primer
Number of subjects: 130
Study 12450709 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 130
Study 10071426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: 240 mg CBS every 12 h for 6 weeks
Number of subjects: 53
Study 10071426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus tetracycline 500 mg every 8 h for 10 days
Number of subjects: 53
Study 10071426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus amoxicillin 750 mg every 12 h for 10 days
Number of subjects: 53
Study 10071426 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 53
Study 12836712 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0
Study 1835403 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-1
Number of subjects: 29
Study 1835403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7174214 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme during febrile illness
Number of subjects: 18
Study 7174214 — intervention group
Group type: COMPARATOR
Intervention: Control group (bed rest)
Number of subjects: 18
Study 31560600 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to master an artificial morphological rule (AMR) through exposure and usage; specific tasks included judgment and production tasks.
Number of subjects: 26
Study 31560600 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to judge and produce repeated items of the AMR.
Number of subjects: 26
Study 31560600 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastering task-specific phonological regularities.
Number of subjects: 26
Study 31560600 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization of the AMR to new items.
Number of subjects: 26
Study 28111410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment for 15 days or longer (15DL)
Number of subjects: 0
Study 28111410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment for 14 days or shorter (14DS)
Number of subjects: 0
Study 26108162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT)
Number of subjects: 80
Study 26108162 — intervention group
Group type: COMPARATOR
Intervention: Manual thrombus aspiration (MTA)
Number of subjects: 80
Study 24197826 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS) 5 ml injected into the epidural space before catheter insertion
Number of subjects: 290
Study 24197826 — intervention group
Group type: COMPARATOR
Intervention: No fluid injected into the epidural space before catheter insertion (Control)
Number of subjects: 290
Study 22067058 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate 2-weeks treatment group (N=28)
Number of subjects: 49
Study 22067058 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group (N=21)
Number of subjects: 49
Study 19737980 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 51
Study 19737980 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 51
Study 19737980 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 51
Study 19737980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19737980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 51
Study 17923489 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK364735 (50 to 400 mg single doses, 100 to 600 mg repeated doses for 8 days)
Number of subjects: 79
Study 17923489 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK364735
Number of subjects: 79
Study 17923489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 15100560 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP-Kiwi
Number of subjects: 392
Study 15100560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 11322666 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition and simple intervention for depression in old age
Number of subjects: 0
Study 9476578 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-bearing balloon catheter (group A)
Number of subjects: 42
Study 9476578 — intervention group
Group type: COMPARATOR
Intervention: PTCA without IVUS (group B)
Number of subjects: 42
Study 8179044 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio self‐administered questionnaire
Number of subjects: 0
Study 8179044 — intervention group
Group type: COMPARATOR
Intervention: Written self‐administered questionnaire
Number of subjects: 0
Study 8179044 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face interviews
Number of subjects: 0
Study 3148149 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (800 mg)
Number of subjects: 26
Study 3148149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28948295 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chest and abdominopelvic CT-scan
Number of subjects: 140
Study 28948295 — intervention group
Group type: COMPARATOR
Intervention: Selective CT-scan according to clinical presentation
Number of subjects: 140
Study 28948295 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chest CT-scan
Number of subjects: 140
Study 26400648 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant movement condition
Number of subjects: 0
Study 26400648 — intervention group
Group type: COMPARATOR
Intervention: Irrelevant movement condition
Number of subjects: 0
Study 24628007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes group
Number of subjects: 17
Study 24628007 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance group
Number of subjects: 17
Study 23544125 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d
Number of subjects: 72
Study 23544125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d
Number of subjects: 72
Study 23544125 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d plus Ezetimibe 10 mg/d
Number of subjects: 72
Study 20598634 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group invited for PSA testing every 2 years (n=10,000)
Number of subjects: 19904
Study 20598634 — intervention group
Group type: COMPARATOR
Intervention: Control group not invited for screening (n=10,000)
Number of subjects: 19904
Study 20598634 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendees of the screening group
Number of subjects: 19904
Study 20598634 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall screening invitation
Number of subjects: 19904
Study 18194486 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogues
Number of subjects: 18
Study 16539561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-speed tungsten-carbide bur (TCB)
Number of subjects: 80
Study 16539561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed TCB
Number of subjects: 80
Study 16539561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof-Lex finishing disks
Number of subjects: 80
Study 16539561 — intervention group
Group type: EXPERIMENTAL
Intervention: Microetcher
Number of subjects: 80
Study 16539561 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 80
Study 14615636 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (standard treatment)
Number of subjects: 0
Study 14615636 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive agents (new treatments)
Number of subjects: 0
Study 10636509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) therapy
Number of subjects: 80
Study 10636509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 80
Study 8959160 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate (MS)
Number of subjects: 75
Study 8959160 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 75
Study 8959160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 1550011 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cholesterol, low-fat, vegetarian diet, stress management, and moderate aerobic exercise
Number of subjects: 0
Study 1550011 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 3998921 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 104
Study 3998921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 30710614 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Infrared Light (NIRL)
Number of subjects: 170
Study 30710614 — intervention group
Group type: COMPARATOR
Intervention: Traditional Overhead White Light (WL)
Number of subjects: 170
Study 30307901 — intervention group
Group type: EXPERIMENTAL
Intervention: Offset Analgesia (OA)
Number of subjects: 17
Study 30307901 — intervention group
Group type: COMPARATOR
Intervention: Control Heat Stimulus (CTL)
Number of subjects: 17
Study 26811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin added to FU + LV
Number of subjects: 12233
Study 26811529 — intervention group
Group type: COMPARATOR
Intervention: FU + LV alone
Number of subjects: 12233
Study 26811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Oxaliplatin and FU + LV)
Number of subjects: 12233
Study 24509454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable staple line reinforcement
Number of subjects: 258
Study 24509454 — intervention group
Group type: COMPARATOR
Intervention: No bioabsorbable staple line reinforcement
Number of subjects: 258
Study 24509454 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 258
Study 21834731 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR website
Number of subjects: 56
Study 21834731 — intervention group
Group type: COMPARATOR
Intervention: Information-only website
Number of subjects: 56
Study 21834731 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 56
Study 20357251 — intervention group
Group type: EXPERIMENTAL
Intervention: Filarial infections (Fil(+))
Number of subjects: 0
Study 20357251 — intervention group
Group type: COMPARATOR
Intervention: Uninfected individuals (Fil(-))
Number of subjects: 0
Study 17319331 — intervention group
Group type: EXPERIMENTAL
Intervention: College Alc (3-hour noncredit version)
Number of subjects: 0
Study 17319331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15321815 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Zn (Zn group)
Number of subjects: 680
Study 15321815 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Fe (Fe group)
Number of subjects: 680
Study 15321815 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Fe and 10 mg Zn (Fe+Zn group)
Number of subjects: 680
Study 15321815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study 11260566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (CFP)
Number of subjects: 33
Study 11260566 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (CFZ)
Number of subjects: 33
Study 9843082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh-dose methylcobalamin (25 mg/day, intramuscularly, for 14 days)
Number of subjects: 24
Study 9843082 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methylcobalamin (0.5 mg/day, intramuscularly, for 14 days)
Number of subjects: 24
Study 7853070 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Medical Reference (QMR)
Number of subjects: 16
Study 7853070 — intervention group
Group type: COMPARATOR
Intervention: Textbooks without QMR
Number of subjects: 16
Study 2666251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult test with rehydration of slides
Number of subjects: 0
Study 2666251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult test
Number of subjects: 0
Study 22515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate (100 mg, injected every 4th week)
Number of subjects: 61
Study 22515 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate (25 or 37.5 mg, injected every 3rd week)
Number of subjects: 61
Study 31934897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg b.i.d.
Number of subjects: 629
Study 31934897 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 629
Study 31136834 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC) + referral to Psychologically Informed Physical Therapy (PIPT)
Number of subjects: 1860
Study 31136834 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based care (GBC)
Number of subjects: 1860
Study 31136834 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1860
Study 28272748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% nitrous oxide in oxygen mixture
Number of subjects: 77
Study 28272748 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane with 40% oxygen in air (control group)
Number of subjects: 77
Study 25366931 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC)
Number of subjects: 4407
Study 25366931 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4407
Study 23497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended anticoagulation treatment (continuing warfarin treatment for a further 2 years)
Number of subjects: 0
Study 23497371 — intervention group
Group type: COMPARATOR
Intervention: Routine anticoagulation treatment (discontinuing warfarin treatment after 3-6 months)
Number of subjects: 0
Study 23497371 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels measured using Roche Cobas h 232 POC device
Number of subjects: 0
Study 23497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Villalta scale for signs and symptoms of post-thrombotic syndrome (PTS)
Number of subjects: 0
Study 23497371 — intervention group
Group type: EXPERIMENTAL
Intervention: VEINES and EQ5D quality of life questionnaires
Number of subjects: 0
Study 21086242 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (12 weeks, 3 days/week, 10 whole body resistance exercises, 3 sets at 8-RM)
Number of subjects: 21